Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Focus on the use of tagraxofusp and clinical considerations Review
| Authors: | Pemmaraju, N.; Madanat, Y. F.; Rizzieri, D.; Fazal, S.; Rampal, R.; Mannis, G.; Wang, E. S.; Foran, J.; Lane, A. A. |
| Review Title: | Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Focus on the use of tagraxofusp and clinical considerations |
| Abstract: | BPDCN is an aggressive myeloid malignancy with a poor prognosis. It derives from the precursors of plasmacytoid dendritic cells and is characterized by CD123 overexpression, which is seen in all patients with BPDCN. The CD123-directed therapy tagraxofusp is the only approved treatment for BPDCN; it was approved in the US as monotherapy for the treatment of patients aged ≥2 years with treatment-naive or relapsed/refractory BPDCN. Herein, we review the available data supporting the utility of tagraxofusp in treating patients with BPDCN. In addition, we present best practices and real-world insights from clinicians in academic and community settings in the US on how they use tagraxofusp to treat BPDCN. Several case studies illustrate the efficacy of tagraxofusp and discuss its safety profile, as well as the prevention, mitigation, and management of anticipated adverse events. © 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | immunohistochemistry; cancer chemotherapy; clinical article; human tissue; treatment outcome; treatment response; aged; myeloproliferative disorders; unclassified drug; gene mutation; myeloproliferative disorder; histopathology; review; case report; drug efficacy; cancer patient; cytarabine; methotrexate; cancer staging; flow cytometry; cancer diagnosis; metabolism; computer assisted tomography; skin biopsy; dendritic cell; thrombocytopenia; furosemide; pathology; fever; hypotension; dendritic cells; albumin; pethidine; hematologic neoplasms; recombinant fusion proteins; lumbar puncture; bone marrow biopsy; skin examination; splenomegaly; long term care; peripheral edema; donor lymphocyte infusion; disease management; cerebrospinal fluid analysis; treatment refusal; lymphadenopathy; tachycardia; azacitidine; hematologic disease; urine volume; protein tet2; fusion protein; oncogene n ras; capillary leak syndrome; cd56 antigen; peptides and proteins; protein asxl1; albumin blood level; methylprednisolone sodium succinate; high throughput sequencing; infusion related reaction; cd123 antigen; interleukin-3 receptor alpha subunit; very elderly; protein nras; humans; prognosis; human; male; venetoclax; meprednisone; patient engagement; tagraxofusp; blastic plasmacytoid dendritic cell neoplasm; cd-123 directed therapy; elzonris; sl-401; protein srsf2; protein zrsr2; il3ra protein, human |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 65 |
| Issue: | 5 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2024-01-01 |
| Start Page: | 548 |
| End Page: | 559 |
| Language: | English |
| DOI: | 10.1080/10428194.2024.2305288 |
| PUBMED: | 38391126 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Erratum issued, see DOI: 10.1080/10428194.2024.2327797 -- Source: Scopus |
